Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Genmab A/S GMAB
$41.50
-$0.45 (-1.10%)
На 18:01, 12 мая 2023
-13.25%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
27445629010.00000000
-
week52high
47.50
-
week52low
26.19
-
Revenue
14595000000
-
P/E TTM
32
-
Beta
0.72099200
-
EPS
1.24000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 04:00
Описание компании
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 22 авг 2022 г. |
| Morgan Stanley | Underweight | Underweight | 15 авг 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 11 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 20 июл 2022 г. |
| BMO Capital | Market Perform | 24 июн 2022 г. | |
| William Blair | Market Perform | 14 ноя 2022 г. | |
| Morgan Stanley | Underweight | Underweight | 14 ноя 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 10 ноя 2022 г. |
| Morgan Stanley | Underweight | Underweight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Genmab A/S (GMAB) Q4 2022 Earnings Call Transcript
Seeking Alpha
22 февр 2023 г. в 15:34
Genmab A/S (GMAB) Q4 2022 Results Conference Call February 22, 2023 12:00 PM ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Judith Klimovsky - Chief Development Officer Anthony Mancini - Chief Operating Officer Tahamtan Ahmadi - Chief Medical Officer Conference Call Participants Matthew Harrison - Morgan Stanley Peter Verdult - Citigroup Sachin Jain - Bank of America Jonathan Chang - SVB Securities Elizabeth Walton - Crédit Suisse AG Paul Jeng - Guggenheim Securities Yaron Werber - Cowen and Company Emily Field - Barclays Asthika Goonewardene - Truist Securities, Inc Etzer Darout - BMO Capital Markets Matthew Phipps - William Blair & Company Operator Hello, and welcome to the Genmab Full-year 2022 Conference Call. As a reminder, this conference call is being recorded.
4 Top Stocks to Buy on Earnings Beat Potential
Zacks Investment Research
08 февр 2023 г. в 09:47
These top-ranked stocks are likely to beat on the bottom line in their next releases. These stocks include Genmab (GMAB), Hologic (HOLX), ServiceNow (NOW) and Splunk (SPLK).
Genmab: High-Quality Biotech Darling, But Lacks Meaningful Catalysts In The Near Term
Seeking Alpha
31 янв 2023 г. в 06:48
Genmab (GMAB) is a Danish commercial biopharma company with a leading technology and track record in innovative antibody-based therapeutics. Darzalex royalty revenue is the key driver of the stock price and the bedrock of Genmab's strong performance during 2021-2022.
GILD or GMAB: Which Is the Better Value Stock Right Now?
Zacks Investment Research
23 янв 2023 г. в 12:48
GILD vs. GMAB: Which Stock Is the Better Value Option?
New Strong Buy Stocks for January 11th
Zacks Investment Research
11 янв 2023 г. в 09:47
GMAB, OSW, ACDC, EVBG and MTG have been added to the Zacks Rank #1 (Strong Buy) List on January 11 , 2023.